Incretin-based drugs and the risk of cholangiocarcinoma among patients with type 2 diabetes.

Abrahami D, Douros A, Yin H, Yu OHY, Faillie JL, Platt RW, Bouganim N, Azoulay L. Incretin-based drugs and the risk of cholangiocarcinoma among patients with type 2 diabetes. BMJ. 2018 Dec 5;363:k4880.

View All Publications